Global Proteomics Partnering Terms and Agreements 2014-2019 - Deal Type, Industry Sector, Stage Of Development, Technology Type, Therapeutic Indication

Dublin, Dec. 04, 2019 (GLOBE NEWSWIRE) -- The "Global Proteomics Partnering Terms and Agreements 2014 to 2019" report has been added to ResearchAndMarkets.com's offering.

The Global Proteomics Partnering Terms and Agreements 2014 to 2019 report provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Proteomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Proteomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Proteomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

In addition, a comprehensive appendix is provided organized by Proteomics partnering company A-Z, deal type definitions and Proteomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Proteomics partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Proteomics technologies and products.

Report scope

Global Proteomics Partnering Terms and Agreements 2014 to 2019 includes:

Trends in Proteomics dealmaking in the biopharma industry since 2014
Analysis of Proteomics deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Proteomics deals
Access to over 140 Proteomics deal records and contract documents where available
The leading antibody deals by value since 2014
Most active Proteomics dealmakers since 2014
The leading Proteomics partnering resources

Available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Proteomics dealmaking
2.1. Introduction
2.2. Proteomics partnering over the years
2.3. Most active Proteomics dealmakers
2.4. Proteomics partnering by deal type
2.5. Proteomics partnering by therapy area
2.6. Proteomics partnering by industry sector
2.7. Deal terms for Proteomics partnering
2.7.1 Proteomics partnering headline values
2.7.2 Proteomics deal upfront payments
2.7.3 Proteomics deal milestone payments
2.7.4 Proteomics royalty rates
2.8. The anatomy of an Proteomics deal
2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 - Leading Proteomics deals
3.1. Introduction
3.2. Top Proteomics deals by value

Chapter 4 - Most active Proteomics dealmakers
4.1. Introduction
4.2. Most active Proteomics dealmakers
4.3. Most active Proteomics partnering company profiles

Chapter 5 - Proteomics contracts dealmaking directory
5.1. Introduction
5.2. Proteomics contracts dealmaking directory

Chapter 6 - Proteomics dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 - Proteomics deals by company A-Z
Appendix 2 - Proteomics deals by stage of development
Appendix 3 - Proteomics deals by deal type
Appendix 4 - Proteomics deals by therapy area
Appendix 5 -Deal type definitions

Companies Mentioned

3SBio
A*STAR Bioinformatics Institute
AB Analitica
Abbvie
Ablynx
Absorption Systems
Advaita
Advanced Manufacturing Fund
Aelan Cell Technologies
Affibody
Albumedix
Alexion Pharmaceuticals
Amunix
Analytical Testing Laboratory
Anteo Diagnostics
Anthera Pharmaceuticals
Arbor Vita
Arbutus
ArmaGen
AstraZeneca
Asuragen
Aurigene Discovery Technologies
Auven Therapeutics
Avera Heart Hospital of South Dakota
Axil Scientific
Bayer
Bellus Health
Berg
Bio-Techne
Biocartis
Biodesix
Biognosys
BioNova Cientifica
Biotest
bioVidria
Bioyong
BluePen Biomarkers
Boehringer Ingelheim
Bristol-Myers Squibb
Bruker
c-LEcta
California Institute for Quantitative Biosciences (QB3)
Cambridge Isotope Laboratories
Cambridge Research Biochemicals
Camino Partnership
Caprion Biosciences
Caprion Proteomics
Caris Life Sciences
Casebia Therapeutics
Catabasis Pharmaceuticals
Celares
Celgene
Celsee
Center for Human Immunology
Autoimmunity and Inflammation
Centogene
Centre For Proteomic & Genomic Research
Chan Soon-Shiong Institute of Molecular Medicine
Children's Hospital of Orange County
Children's Medical Research Institute
Children's Hospital Colorado
Chugai Pharmaceutical
Cisbio Bioassays
Codexis
Core Diagnostics India
COTA
CPR Pharma Services
CRISPR Therapeutics
Cyclenium Pharma
Datavant
Delphi Genetics
Dimerix Biosciences
Dnastar
DuPont Industrial Biosciences
Dyadic International
Edico Genome
Eleven Biotherapeutics
Eli Lilly
EMD Millipore
EMD Serono
Epic Sciences
Epicypher
Epivax
Eucodis Bioscience
Eureka Eurostars
Eurobio
European Bioinformatics Institute
Evogen
Evosep
Exactis Innovation
Fluidigm
FORMA Therapeutics
Foundation for the National Institutes of Health (FNIH)
Fred Hutchinson Cancer Research Center
French National Research Agency
Gallus Biopharmaceuticals
Genzyme
Gladstone Institutes
GlaxoSmithKline
Global Centers for Therapeutic Innovation
Global Genomics Group
GNS Healthcare
Grace Bio-Labs
Gritstone Oncology
Halozyme Therapeutics
Harvard Medical School
Heptares Therapeutics
Icahn School of Medicine at Mount Sinai
Illumina
Immune Design
IncellDx
Indiana University
Indivumed
Inhibikase Therapeutics
Innova Biosciences
Institute for Systems Biology
Institute of Bioinformatics
Integrated Diagnostics
Integrated DNA Technologies
Inventiva
Invetech
INVISTA Technologies
Israeli National Authority for Technological Innovation
Janssen Diagnostics
Jeffrey Modell Foundation
JPT Peptide Technologies
Karolinska Institute
Karolinska University Hospital
KineMed
Labgene Scientific
LifeArc
Luxembourg Institute of Health
Mariel Therapeutics
Massachusetts General Hospital
MD Anderson Cancer Center
Medgenics
Medical University of South Carolina
MedImmune
Memorial Sloan Kettering Cancer Center
Merck and Co
Metabolon
Moderna Therapeutics
Mologic
MRM Proteomics
Munich Technical University
NanoString Technologies
NantBioScience
NantHealth
National Heart
Lung and Blood Institute
National Institute for Bioprocessing Research and Training
National Institute of Allergy and Infectious Diseases
National Institutes of Health
NEC
New Objective
Northwestern Medicine Developmental Therapeutics Institute
Northwestern University
Nuclea Biotechnologies
Nurix
NX Prenatal
NYU Langone Medical Center
Olink Bioscience
OmicScouts
Omni Bio Pharmaceutical
Omniox
OncoDNA
Orion
Oxford BioTherapeutics
Paradigm
Parkinson's Institute and Clinical Center
Pelago Bioscience
Perthera
Pfizer
Pharmstandard
Pharm Tech Korea
PhileKorea
Positive Bioscience
Pressure BioSciences
Probiodrug AG
Pronutria
Proteomics International
Prothelia
pSivida
Purdue Pharma
Purdue Research Foundation
Purolite
Reaction Biology
Replicel Life Sciences
rEVO Biologics
Roche
Saint Louis University
Saromics
Scienion
Sciex
Scripps Research Institute
Selecta Biosciences
Shire Pharmaceuticals
Sigma-Aldrich
Sigma-Tau
Small Business Innovation Research
SOLTI
SomaLogic
Sorrento Therapeutics
SQI Diagnostics
Stratose
Structural Genomics Consortium
Stryker
Syapse
SYGNIS Pharma
Tanon
Targeted Medical Pharma
Teijin
Tetragenetics
The Hospital for Sick Children
Theranostics Health
Therapure Biopharma
Thermo Fisher Scientific
TME Research
Transgenomic
Translational Drug Development
UCB
University of British Columbia
University of California San Francisco
University of Florida
University of Greifswald
University of Manchester
University of Montreal
University of Nebraska
University of Nevada
University of Oxford
University of Pennsylvania
University of Rostock
University of South Carolina
University of Texas Southwestern Medical Center
US Army
Vigilant Biosciences
VM Pharma
WaferGen Biosystems
Wellcome Trust
Wellcome Trust Sanger Institute
Xbrane Bioscience
Yale University
Ymir Genomics

For more information about this report visit https://www.researchandmarkets.com/r/b53dnp

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

Market News and Data brought to you by Benzinga APIs